Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Ophysio Inc
Profile last edited on: 1/29/18      CAGE: 62U38      UEI:

Business Identifier: Stem cell research
Year Founded
2010
First Award
2015
Latest Award
2019
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1450 Nw 10th Avenue Room 6006
Miami, FL 33136
   (949) 275-6398
   N/A
   N/A
Location: Single
Congr. District: 24
County: Miami-Dade

Public Profile

Ophysio Inc. works in stem cell research. The company was founded by Juan Domínguez-Bendala, Director of Stem Cell Development for Translational Research at the Diabetes Research Institute. Domínguez-Bendala's background is in both stem cell research and genetic engineering. His particular focus is on the use of stem cells to obtain pancreatic islets that could potentially be transplanted into patients with type 1 diabetes. He is also working on new methods for expansion/ regeneration of pancreatic beta cells

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$673,200
Phase II Dollars
$1,443,038
Total Awarded
$2,116,238

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 1 NIH $224,339
Project Title: Targeting a Double Fail-Safe Construct to Prevent Tumorigenesis and Select Pancreatic Endocrine Cells from Human Embryonic Stem Cells
2017 1 NIH $223,876
Project Title: Preclinical characterization of THR-123 to induce pancreatic beta cell regeneration (Phase I)
2017 2 NIH $1,668,023
Project Title: In Vitro Maturation of BMP-7-Responsive Pancreatic Beta Cell Progenitors by Oxygen Modulation Technology

Key People / Management

  Juanlatta Dominguez-Bendala -- Founder

  Paul Latta

Company News

There are no news available.